Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 1.5t

Novo Nordisk Valuation

Is NOVO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NOVO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 1.27k
Fair Value
73.3% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: NOVO B (DKK338.7) is trading below our estimate of fair value (DKK1268.39)

Significantly Below Fair Value: NOVO B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NOVO B?

Key metric: As NOVO B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NOVO B. This is calculated by dividing NOVO B's market cap by their current earnings.
What is NOVO B's PE Ratio?
PE Ratio13.6x
EarningsDKK 111.07b
Market CapDKK 1.54t

Price to Earnings Ratio vs Peers

How does NOVO B's PE Ratio compare to its peers?

The above table shows the PE ratio for NOVO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.4x
ALK B ALK-Abelló
45.2x16.95%DKK 45.1b
HLUN B H. Lundbeck
11.9x2.96%DKK 39.9b
AZN AstraZeneca
30.3x14.71%UK£185.7b
NOVN Novartis
18.1x8.01%CHF 197.6b
NOVO B Novo Nordisk
13.6x9.05%DKK 1.5t

Price-To-Earnings vs Peers: NOVO B is good value based on its Price-To-Earnings Ratio (13.6x) compared to the peer average (26.4x).

Price to Earnings Ratio vs Industry

How does NOVO B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NOVO B 13.6xIndustry Avg. 21.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NOVO B is good value based on its Price-To-Earnings Ratio (13.6x) compared to the European Pharmaceuticals industry average (21.1x).

Price to Earnings Ratio vs Fair Ratio

What is NOVO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NOVO B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.6x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: NOVO B is good value based on its Price-To-Earnings Ratio (13.6x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NOVO B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 338.70
DKK 459.84
+35.77%
19.30%DKK 612.00DKK 340.00n/a19
Sep ’26DKK 365.10
DKK 465.30
+27.44%
19.76%DKK 620.00DKK 340.00n/a20
Aug ’26DKK 308.80
DKK 521.60
+68.91%
23.42%DKK 750.00DKK 360.00n/a20
Jul ’26DKK 438.35
DKK 634.76
+44.81%
20.20%DKK 900.00DKK 405.00n/a21
Jun ’26DKK 453.65
DKK 678.82
+49.63%
23.01%DKK 1,000.00DKK 405.00n/a22
May ’26DKK 444.25
DKK 699.59
+57.48%
22.61%DKK 1,000.00DKK 405.00n/a23
Apr ’26DKK 479.00
DKK 794.00
+65.76%
21.55%DKK 1,150.00DKK 450.00n/a23
Mar ’26DKK 644.50
DKK 813.17
+26.17%
20.53%DKK 1,150.00DKK 515.00n/a24
Feb ’26DKK 607.30
DKK 816.68
+34.48%
22.05%DKK 1,150.00DKK 515.00n/a22
Jan ’26DKK 624.20
DKK 880.73
+41.10%
22.02%DKK 1,150.00DKK 560.00n/a22
Dec ’25DKK 757.30
DKK 938.04
+23.87%
20.30%DKK 1,150.00DKK 560.00n/a24
Nov ’25DKK 768.90
DKK 944.58
+22.85%
20.43%DKK 1,150.00DKK 560.00n/a24
Oct ’25DKK 798.20
DKK 950.04
+19.02%
20.25%DKK 1,150.00DKK 560.00n/a25
Sep ’25DKK 938.10
DKK 950.81
+1.35%
20.06%DKK 1,200.00DKK 560.00DKK 365.1026
Aug ’25DKK 915.80
DKK 965.65
+5.44%
18.66%DKK 1,200.00DKK 560.00DKK 308.8026
Jul ’25DKK 1,004.60
DKK 952.15
-5.22%
18.30%DKK 1,200.00DKK 560.00DKK 438.3526
Jun ’25DKK 927.30
DKK 917.31
-1.08%
18.47%DKK 1,120.00DKK 530.00DKK 453.6526
May ’25DKK 897.70
DKK 904.20
+0.72%
19.41%DKK 1,120.00DKK 530.00DKK 444.2525
Apr ’25DKK 881.30
DKK 894.24
+1.47%
19.59%DKK 1,120.00DKK 530.00DKK 479.0025
Mar ’25DKK 850.90
DKK 820.08
-3.62%
16.75%DKK 980.00DKK 530.00DKK 644.5024
Feb ’25DKK 786.40
DKK 770.90
-1.97%
18.47%DKK 980.00DKK 450.00DKK 607.3023
Jan ’25DKK 698.10
DKK 720.74
+3.24%
20.44%DKK 875.00DKK 360.00DKK 624.2023
Dec ’24DKK 698.70
DKK 711.35
+1.81%
20.22%DKK 875.00DKK 360.00DKK 757.3023
Nov ’24DKK 687.70
DKK 683.48
-0.61%
21.13%DKK 825.00DKK 360.00DKK 768.9022
Oct ’24DKK 643.90
DKK 648.75
+0.75%
19.72%DKK 810.00DKK 360.00DKK 798.2022
Sep ’24DKK 650.60
DKK 618.30
-4.97%
18.06%DKK 775.00DKK 360.00DKK 938.1022
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
DKK 459.84
Fair Value
26.3% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/09 23:32
End of Day Share Price 2025/09/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 73 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research